PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer
- PMID: 29269345
- DOI: 10.1158/2159-8290.CD-RW2017-238
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer
Abstract
The HA-degrading drug PEGPH20 plus standard therapy extends survival in metastatic pancreatic cancer.
©2018 American Association for Cancer Research.
Comment on
-
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12. J Clin Oncol. 2018. PMID: 29232172 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
